10,777 reports of this reaction
6.1% of all FINGOLIMOD HCL reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for FINGOLIMOD HCL, manufactured by Novartis Pharmaceuticals Corporation. There are 10,777 FDA adverse event reports linking FINGOLIMOD HCL to FATIGUE. This represents approximately 6.1% of all 175,367 adverse event reports for this drug.
Patients taking FINGOLIMOD HCL who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among FINGOLIMOD HCL users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for FINGOLIMOD HCL:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 10,777 FDA reports for FINGOLIMOD HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 6.1% of all adverse event reports for FINGOLIMOD HCL, making it one of the most commonly reported side effect.
If you experience fatigue while taking FINGOLIMOD HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.